Wed.Jun 05, 2024

article thumbnail

Bristol Myers puts more than 860 jobs on chopping block in NJ as $1.5B savings campaign rolls ahead

Fierce Pharma

The scope of Bristol Myers Squibb’s $1.5 billion savings drive is beginning to come into focus. | Starting this month, BMS will begin the process of laying off around 863 employees in Lawrenceville, New Jersey, according to a Worker Adjustment and Retraining Notification (WARN) alert from the state. The move forms part of BMS’ campaign to shave off $1.5 billion in costs by the end of 2025, a company spokesperson said over email.

321
321
article thumbnail

Regenerative cell therapy biotech uses IPO to blast into human trials

PharmaVoice

Bucking conventional fundraising, FibroBiologics’ CEO Pete O’Heeron explains why the biotech company bet on themselves in the public market.

Marketing 119
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

From one juggernaut to another: Lilly CFO Anat Ashkenazi takes same role at tech giant Alphabet

Fierce Pharma

After 23 years at Eli Lilly, including the last three as its CFO, Anat Ashkenazi is leaving to take the same role at Google's parent company Alphabet.

301
301
article thumbnail

First rare disease therapies chosen for FDA START programme

pharmaphorum

An initiative set up by the FDA to accelerate the development of therapies for rare disease in the same way that Operation Warp Speed delivered COVID-19 vaccine has chosen its first pilot programme candidates.

FDA 107
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Lilly touts fibrosis win as it pads case for tirzepatide in MASH

Fierce Pharma

Back in February, Eli Lilly teased “clinically meaningful” results around the ability of its dual GLP-1/GIP med tirzepatide to curb fibrosis in patients with fatty liver disease. | Back in February, Eli Lilly teased “clinically meaningful” results around the ability of its dual GLP-1/GIP med tirzepatide to curb fibrosis in patients with fatty liver disease.

Patients 278
article thumbnail

Another Retailer Bites the Dust. Is There Still Hope for Retailers After Dollar General/DocGo End Pilot?

MedCity News

Dollar General and DocGo have mutually decided to end their mobile clinic pilot. The decision comes as numerous retailers have struggled in the healthcare sector. The post Another Retailer Bites the Dust. Is There Still Hope for Retailers After Dollar General/DocGo End Pilot? appeared first on MedCity News.

Retail 105

More Trending

article thumbnail

ASCO: KRAS upstarts set their sights on NSCLC market

pharmaphorum

KRAS inhibitors from Eli Lilly, Genfleet, and InxMed make their case for use in NSCLC at ASCO, as they case down Amgen and Bristol-Myers Squibb's market drugs

Marketing 107
article thumbnail

CCC Helps Establish Leiden Institute for FAIR and Equitable Science (LIFES) as a Founding Member

Copyright Clearance Center

June 5, 2024 – Danvers, Mass. – CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, announced its collaboration with key industry stakeholders to launch the Leiden Institute for FAIR and Equitable Science (LIFES). In recognition of the challenges that exist with data reuse within the global research community, LIFES is a joint effort by an international public-private partnership of eleven academic and private organizations to build a wide and diverse network

Ethics 98
article thumbnail

At BIO, Novo Nordisk’s Top Dealmaker Talks M&A Strategy and What’s Next After GLP-1s

MedCity News

Novo Nordisk’s focus on diabetes and obesity shape its business development work, but the company is also exploring other areas. Top Novo Nordisk M&A executive John McDonald discussed his company’s strategy during a session at the BIO conference in San Diego. The post At BIO, Novo Nordisk’s Top Dealmaker Talks M&A Strategy and What’s Next After GLP-1s appeared first on MedCity News.

Biopharma 100
article thumbnail

The Intersection of Chemistry, Robotics, and AI in Drug Discovery (BIO 2024)

PharmaTech

Lee Cronin, founder and CEO of Chemify, discusses the combination of digital chemistry, robotics, and AI in the drug discovery space.

110
110
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Annual Benefit Consultant Report Offers Window into Self-Insured Employers’ 2024 Benefit Priorities Including Emphasis on Care Navigation

MedCity News

More than 100 skilled consultants to self-insured employers shared their perspectives on the changing dynamics in healthcare benefits in MedCity News’ second annual 2024 Benefit Consultant Sentiment Index (The Index): Benefit Consultants’ Perspective on Shifting Employer Healthcare Landscape. The report functions as an insider’s guide to understanding how healthcare trends are shaping employer benefit decisions from the perspective of consultants.

article thumbnail

Gilead, Ipsen build the case for their PBC drugs at EASL

pharmaphorum

Gilead Sciences is just a few weeks away from an FDA decision on seladelpar for rare liver disease primary biliary cholangitis (PBC) and will be buoyed by new data pointing to its long-term efficacy and safety.

Safety 95
article thumbnail

Healthcare’s Data Problem: So Much Data, yet So Little Data Fidelity

MedCity News

As the volume of healthcare data accelerates, health system leaders must take critical steps to elevate the quality, completeness and accessibility of data they capture, manage and aggregate. The post Healthcare’s Data Problem: So Much Data, yet So Little Data Fidelity appeared first on MedCity News.

article thumbnail

Cyberattack disrupts patient care at London hospitals

pharmaphorum

NHS hospitals in London have declared a critical incident caused by a ransomware attack on a pathology services provider, leading to cancelled procedures and patients having to be transferred to different care providers. The attack on Synnovis has had an impact on patient care at Guy’s and St Thomas’ and King’s College Hospital NHS Foundation Trusts, as well as GP services in southeast London, according to an NHS England statement.

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Making the Transition to Value-Based Specialty Care

MedCity News

We’re in for a bumpy ride near term, but value-based specialty care (VBSC) is coming and – if done right – has the potential to transform how we care for millions of patients. The post Making the Transition to Value-Based Specialty Care appeared first on MedCity News.

article thumbnail

Biologic demonstrates durable tumour regression in rectal cancer

European Pharmaceutical Review

New clinical data from a Phase II trial for rectal cancer has revealed a 100 percent clinical complete response rate following first-line therapy with Jemperli (dostarlimab-gxly). These findings from GSK reflect outcomes from 42 patients with mismatch repair deficient (dMMR) locally advanced rectal cancer who finished the treatment. The trial investigated the therapy as an alternative to surgery.

Safety 85
article thumbnail

PHTI backs virtual therapies for musculoskeletal disorders

pharmaphorum

PHTI's latest report finds that digital therapies for musculoskeletal conditions like low back pain can deliver clinically meaningful benefits

91
article thumbnail

New pDNA Facility in the Works for Bionova Scientific

Pharmaceutical Commerce

The development and manufacturing plant will be constructed in Texas, and is expected to become operational by Q1 2025.

article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

Be Bio’s haemophilia B treatment gains FDA orphan drug status

Pharmaceutical Technology

The US FDA has granted orphan drug designation to Be Biopharma’s (Be Bio) BE-101 for the treatment of haemophilia B.

FDA 98
article thumbnail

Innovating small molecule injectables: market forecast to 2033

European Pharmaceutical Review

A report by the Business Research Company predicts that the small molecule injectable drugs market will value $355.14 billion in 2028. As such, the compound annual growth rate (CAGR) is expected to be 12.8 percent up to this period. Factors that are anticipated to facilitate this growth of the market include personalised treatments , supply chain optimisation and use of real-world evidence, according to the research.

article thumbnail

Critical Year Ahead for the 340B Drug Pricing Program

Pharmaceutical Commerce

The courts reversed certain key guidance documents issued by the Health Resources and Services Administration for the 340B Program, which raises uncertainty.

81
article thumbnail

INVEST Pitch Perfect Spotlight: CoraVie Medical’s Mission to Transform the Way We Monitor Blood Pressure

MedCity News

CoraVie Medical, a startup developing an implantable continuous blood pressure monitor, recently won the medical devices track of MedCity News’ INVEST Pitch Perfect contest. The pre-revenue company’s remote management solution monitors for the early detection of dangerous blood pressure levels to prevent crises that could lead to heart attack, stroke, kidney failure or death.

Medical 71
article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

Scientists push for ‘greener’ drugs in published study

Pharmaceutical Technology

5 June marks World Environment Day, an annual celebration that encourages global awareness and action to protect the environment.

72
article thumbnail

Resolution unveils data for liver disease treatment at EASL 2024

PharmaTimes

Extended phase 2 study highlights macrophage cell therapy’s efficacy

93
article thumbnail

Pharma Pulse 6/5/24: Polypharmacy and the Pivotal Role of the Payer, Patients and Data Disrupt the Industry & more

Pharmaceutical Commerce

The latest news for pharma industry insiders.

Pharma 105
article thumbnail

Sanofi’s Sarclisa shows significant promise in treating myeloma

PharmaTimes

Phase 3 research suggests a significant leap forward in myeloma management

article thumbnail

Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

article thumbnail

Networking Tips for Medical Sales Recruiters: Building Connections for Talent Acquisition Success

Rep-Lite

In the highly competitive medical sales industry, finding top-tier talent is a constant challenge. The power of networking can be used to foster strong connections, and it is at this point medical sales recruiters gain a significant edge in attracting and securing the best candidates. At Rep-Lite, we understand the importance of building a robust network.

article thumbnail

Impact of Biosecure Act on the Pharma Industry (BIO 2024)

PharmaTech

Pharmaceutical Technology® spoke with Parviz Shamlou, senior vice-president of Science and Technology, Abzena, about the impact of the Biosecure Act on the bio/pharmaceutical industry, as well as the progress of continuous manufacturing in biopharma.

article thumbnail

Building Relationships In Medical Sales And All About Wound Care Pathology With Zac Dotinga

Evolve Your Success

Unlock the secrets to thriving in the specialized field of wound care diagnostics with insights from Zac Dotinga, Assistant Regional Manager at Advanced Pathology Solutions. This episode promises to illuminate the intricacies of working with podiatry offices and wound care centers, sharing how pathology services, like confirming fungal infections, play a pivotal role.

article thumbnail

The art of software

pharmaphorum

In this episode of the pharmaphorum podcast, web editor Nicole Raleigh speaks with Rob Pears, VP and head of automotive, manufacturing, and life sciences at Capgemini, which partners with companies to transform and manage their business by harnessing the power of technology.

article thumbnail

Roles and Responsibilities of Specialized Clinical Supply Experts

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.